
Genetic Technologies Limited GENE
Annual report 2022
added 08-30-2022
Genetic Technologies Limited Deferred Revenue 2011-2026 | GENE
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Genetic Technologies Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 77.3 K | 153 K | 321 K | 267 K | 164 K |
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 321 K | 77.3 K | 196 K |
Deferred Revenue of other stocks in the Diagnostics research industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
7.53 M | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
1.34 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
441 M | $ 114.87 | -0.65 % | $ 34.9 B | ||
|
Accelerate Diagnostics
AXDX
|
547 K | - | -61.36 % | $ 2.46 M | ||
|
Aspira Women's Health
AWH
|
489 K | - | -6.19 % | $ 10.5 M | ||
|
Chembio Diagnostics
CEMI
|
1.61 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
14.8 K | $ 1.63 | -1.21 % | $ 2.17 M | ||
|
Castle Biosciences
CSTL
|
6.62 M | $ 24.7 | -1.12 % | $ 686 M | ||
|
CareDx, Inc
CDNA
|
4.65 M | $ 21.91 | 0.27 % | $ 1.17 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
19 K | - | - | $ 562 M | ||
|
DermTech
DMTK
|
196 K | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
2.68 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
4.14 M | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
2.23 M | $ 15.3 | -1.92 % | $ 463 M | ||
|
Global Cord Blood Corporation
CO
|
458 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
13.5 M | - | 1.08 % | $ 308 M | ||
|
Genetron Holdings Limited
GTH
|
8.42 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
210 M | $ 166.79 | -2.59 % | $ 8.27 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
733 M | - | - | $ 10.7 B | ||
|
HTG Molecular Diagnostics
HTGM
|
185 K | - | -20.0 % | $ 1.06 M | ||
|
Guardant Health
GH
|
50.8 M | $ 83.09 | -6.11 % | $ 10.4 B | ||
|
Koninklijke Philips N.V.
PHG
|
1.24 B | $ 27.12 | -1.53 % | $ 20 B | ||
|
Illumina
ILMN
|
260 M | $ 126.92 | -1.24 % | $ 20.2 B | ||
|
Heska Corporation
HSKA
|
5.08 M | - | - | $ 1.31 B | ||
|
Interpace Biosciences
IDXG
|
54 K | $ 1.93 | - | $ 8.54 M | ||
|
Lantheus Holdings
LNTH
|
132 K | $ 83.55 | -0.67 % | $ 5.64 B | ||
|
QIAGEN N.V.
QGEN
|
57.1 M | - | - | $ 10.6 B | ||
|
Medpace Holdings
MEDP
|
854 M | $ 409.65 | -2.78 % | $ 11.8 B | ||
|
ICON Public Limited Company
ICLR
|
1.61 B | $ 102.49 | -0.7 % | $ 8.45 B | ||
|
Laboratory Corporation of America Holdings
LH
|
439 M | $ 259.57 | -1.47 % | $ 21.6 B | ||
|
NeoGenomics
NEO
|
851 K | $ 9.02 | 4.76 % | $ 1.16 B | ||
|
Neogen Corporation
NEOG
|
5.56 M | $ 9.34 | -1.16 % | $ 2.03 B | ||
|
National Research Corporation
NRC
|
16.2 M | $ 16.84 | -1.58 % | $ 377 M | ||
|
Myriad Genetics
MYGN
|
32.7 M | $ 4.84 | 0.21 % | $ 448 M | ||
|
Natera
NTRA
|
10.8 M | $ 200.17 | -2.06 % | $ 19.7 B | ||
|
Invitae Corporation
NVTA
|
4.81 M | - | - | $ 21.2 M | ||
|
OpGen
OPGN
|
25.9 K | - | -16.95 % | $ 1.54 M | ||
|
Organovo Holdings
ONVO
|
525 K | - | -2.3 % | $ 19.4 M | ||
|
PerkinElmer
PKI
|
160 M | - | -0.91 % | $ 14.7 B | ||
|
Precipio
PRPO
|
282 K | $ 31.75 | 3.42 % | $ 51 M | ||
|
Personalis
PSNL
|
3.1 M | $ 5.5 | -7.72 % | $ 326 M | ||
|
Senseonics Holdings
SENS
|
628 K | $ 7.18 | -1.24 % | $ 300 M | ||
|
Burning Rock Biotech Limited
BNR
|
143 M | $ 16.65 | -12.64 % | $ 179 M |